The clinical success of BCR-ABL inhibitors for the treatment of CML not only revolutionized the anti-kinase therapy but also enforced the idea to identify the genetic lesions in other neoplastic diseases for therapeutic targeting2, 3, 4. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.